Luxbright AB (publ) (LXB.ST)
SEK 0.75
(-3.62%)
SEK 0.75
(-3.62%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -2.79 Million SEK | -13744.55% |
| 2022 | 189.11 Thousand SEK | -90.46% |
| 2021 | 1.98 Million SEK | 25.92% |
| 2020 | 1.57 Million SEK | -27.73% |
| 2019 | 2.17 Million SEK | -22.23% |
| 2018 | 2.8 Million SEK | 132.14% |
| 2017 | 1.2 Million SEK | 69.05% |
| 2016 | 713.68 Thousand SEK | 138.04% |
| 2015 | -1.87 Million SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 2.08 Million SEK | 115.33% |
| 2024 Q2 | 2.08 Million SEK | 0.0% |
| 2023 Q2 | -623 Thousand SEK | -5.95% |
| 2023 Q4 | -13.59 Million SEK | -1577.98% |
| 2023 FY | -25.8 Million SEK | -13744.55% |
| 2023 Q3 | -810.43 Thousand SEK | -30.09% |
| 2023 Q1 | -588 Thousand SEK | -151.66% |
| 2022 Q2 | -11.11 Million SEK | -3624.29% |
| 2022 Q4 | -233.65 Thousand SEK | -272.04% |
| 2022 Q3 | 135.81 Thousand SEK | 101.22% |
| 2022 Q1 | -298.5 Thousand SEK | -212.01% |
| 2022 FY | 189.11 Thousand SEK | -90.46% |
| 2021 Q1 | 186.5 Thousand SEK | 102.34% |
| 2021 Q2 | -9.51 Million SEK | -5200.27% |
| 2021 Q3 | 108.5 Thousand SEK | 101.14% |
| 2021 Q4 | 266.5 Thousand SEK | 145.62% |
| 2021 FY | 1.98 Million SEK | 25.92% |
| 2020 Q4 | -7.97 Million SEK | -3944.34% |
| 2020 Q2 | -5.06 Million SEK | -2035.56% |
| 2020 Q3 | 207.5 Thousand SEK | 104.1% |
| 2020 FY | 1.57 Million SEK | -27.73% |
| 2020 Q1 | 261.5 Thousand SEK | 104.08% |
| 2019 Q3 | 90.5 Thousand SEK | 101.48% |
| 2019 FY | 2.17 Million SEK | -22.23% |
| 2019 Q4 | -6.41 Million SEK | -7182.88% |
| 2019 Q2 | -6.12 Million SEK | -2444.05% |
| 2019 Q1 | 261.5 Thousand SEK | 0.0% |
| 2018 FY | 2.8 Million SEK | 132.14% |
| 2017 FY | 1.2 Million SEK | 69.05% |
| 2016 FY | 713.68 Thousand SEK | 138.04% |
| 2015 FY | -1.87 Million SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Acarix AB (publ) | 5.29 Million SEK | 152.801% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 100.93% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 100.93% |
| Arcoma AB | 11.07 Million SEK | 125.263% |
| Bactiguard Holding AB (publ) | 139.98 Million SEK | 101.998% |
| BICO Group AB (publ) | 1.83 Billion SEK | 100.153% |
| Boule Diagnostics AB (publ) | 249.71 Million SEK | 101.12% |
| CellaVision AB (publ) | 463.04 Million SEK | 100.604% |
| Clinical Laserthermia Systems AB (publ) | 2.99 Million SEK | 193.323% |
| Chordate Medical Holding AB (publ) | -28.41 Million SEK | 90.157% |
| C-Rad AB (publ) | 66.01 Million SEK | 104.237% |
| Duearity AB (publ) | -4.17 Million SEK | 33.057% |
| Dignitana AB (publ) | 58.97 Million SEK | 104.743% |
| Episurf Medical AB (publ) | -41.8 Million SEK | 93.309% |
| Getinge AB (publ) | 13.43 Billion SEK | 100.021% |
| Scandinavian Real Heart AB (Publ) | -50.21 Million SEK | 94.43% |
| Iconovo AB (publ) | 17.57 Million SEK | 115.912% |
| Integrum AB (publ) | 690.56 Thousand SEK | 505.014% |
| Mentice AB (publ) | 236.38 Million SEK | 101.183% |
| OssDsign AB (publ) | 83.64 Million SEK | 103.344% |
| Paxman AB (publ) | 12.61 Million SEK | 122.166% |
| Promimic AB (publ) | 38.51 Million SEK | 107.262% |
| Qlife Holding AB (publ) | -50.75 Million SEK | 94.489% |
| SciBase Holding AB (publ) | 16.03 Million SEK | 117.44% |
| ScandiDos AB (publ) | 47.55 Million SEK | 105.881% |
| Sectra AB (publ) | 557.55 Million SEK | 100.502% |
| Sedana Medical AB (publ) | 108.98 Million SEK | 102.566% |
| Senzime AB (publ) | 8.33 Million SEK | 133.54% |
| SpectraCure AB (publ) | -9.22 Million SEK | 69.675% |
| Stille AB | 132.17 Million SEK | 102.116% |
| Vitrolife AB (publ) | 1.97 Billion SEK | 100.141% |
| Xvivo Perfusion AB (publ) | 416.91 Million SEK | 100.671% |